Tanzania Medical Device Assessment Timeline: Stage by Stage Working Day Limits

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Tanzania is one of the few African markets that writes assessment timelines into official guidance stage by stage and class by class. Part I §3.4.4 through §3.4.8 of the June 2024 Compendium gives the complete numbers:

StageClauseClasses A / BClasses C / DNotification
Screening and invoicing§3.4.21–2 working days1–2 working days1–2 working days
Scheduling§3.4.4≤10 working days≤20 working days—
Assessment (first + second)§3.4.523 working days40 working daysFirst assessment only
Quality assurance (QA)§3.4.65 working days8 working days—
Administrative processing (Director General approval)§3.4.7≤5 days≤25 days—
Total (excluding queries and site inspections)—≈43 working days≈93 working days5 working days

2. Legal basis

InstrumentNumberPublication dateProvisions
Compendium of Guidelines for Marketing Authorization of Medical Devices, Diagnostics and Laboratory EquipmentNo gazette number (TMDA guidance document)June 2024Part I §3.4.2, §3.4.4, §3.4.5, §3.4.6, §3.4.7, §3.4.8
Guidelines on Good Review Practices for Regulation of Medical DevicesNo gazette number (TMDA guidance document)March 2024Full text

3. Expert insights

Insight 1: The official numbers contain one typographical error, which must be corrected when citing.

The original text of Part I §3.4.5 reads: “The assessment stage is expected to take 23 working days for class A and B devices and 40 working days for class A and B devices”. The second “class A and B” is evidently meant to be class C and D — otherwise the two halves contradict each other. GRZAN reads the C/D figure as 40 working days in external documents, while noting that the figure comes from the official text with a typographical slip, and recommends obtaining written confirmation from TMDA. This is an official text defect, not something an applicant can correct on TMDA’s behalf, but it must be explained clearly to clients so no one later accuses the file of misquoting the guidance.

Insight 2: The authority states expressly that the timelines exclude site inspections.

The note to §3.4.5 reads: “Quality Audit of the manufacturing facilities is also incorporated into the assessment process however, the timelines reflected above do not include the time for conducting site inspections.” This is the single most important practical message in this article: for Classes C and D that trigger a site audit, the 93 working days cover only the document review; the scheduling and execution of the site audit run as an independent period layered on top. Treating 93 working days as a delivery date is the most common planning error in Tanzanian projects. Companies should request the audit availability early, align travel and interpretation resources, and treat any auditor rescheduling as a formal milestone change in the project plan rather than a minor administrative slip.

Insight 3: Notification undergoes first assessment only, with 5 working days of processing.

§3.4.8: “Applications for notification shall only undergo first assessment. The time frame for processing of notification is 5 working days.” This stands in sharp contrast to the dual assessment for registration, and it is the most tangible value of the notification route — not saving dossier work, but saving review layers. For qualifying Class A products, that difference in review depth is what makes the channel commercially meaningful, particularly for consumables with short commercial windows or tender-driven demand cycles where every week of delay carries a direct revenue cost.

Insight 4: 43 and 93 working days are baselines only; a query halts the clock indefinitely.

§3.4.6 provides that once a query is raised, the processing shall halt until the response is received. The official numbers therefore contain no query round-trips at all. The industry claim that Tanzanian registration takes 4–6 months, extending to 9 months for high-risk devices, has not been verified against any official source; handle it as a practical estimate and do not present it as an authority figure.

Insight 5: The scheduling stage itself carries elasticity.

Before giving its numeric caps, §3.4.4 states that the time taken to schedule assessment depends on the complexity of the device and the availability of assessors. The 10 and 20 working days are ceilings, not commitments. Projects with unusual device technologies or assessor scarcity should expect scheduling to consume the full allowance, and should not promise clients the average of the range.

4. Practical recommendations

  1. Quote and schedule externally using the document-review baseline: approximately 43 working days for Classes A/B and approximately 93 working days for Classes C/D, expressly excluding query round-trips and site inspections.
  2. Schedule site audits for C/D projects as a standalone sub-project, never folded into the 93 working days.
  3. Turn query response speed into an internal SLA. The 60-working-day deemed withdrawal rule in §3.4.6 is a hard constraint (see article 09).
  4. Plan notification projects on 5 working days plus 1–2 working days of screening, but remember that samples and payment still sit in front of the clock.

5. Verification checklist

  • □ The review baselines have been confirmed by risk class: 43 working days for A/B, 93 working days for C/D, 5 working days for notification.
  • □ The baseline has been confirmed to exclude query round-trips and site inspections.
  • □ The typographical error in official §3.4.5 has been explained to the client or internally (C/D is 40 working days).
  • □ A separate site-audit schedule has been set for C/D projects.
  • □ The scheduling caps of 10 / 20 working days have been treated as ceilings, not commitments.

Regulatory information verified as of 29 October 2026. All provisions cited in this article were checked against the texts officially published by TMDA (June 2024 Compendium Part I §3.4.2–§3.4.8); the content is re-reviewed whenever the regulations are updated.

  • Local resources in Tanzania: GRZAN can coordinate licensed local responsible persons (LRP) and distributor resources covering online submission, sample delivery, quality audit support and port clearance.
  • Service capabilities: classification determination, route selection between registration and notification, technical documentation (CSDT/STED) preparation and localization, GMDN coding and grouping strategy, clinical evidence organization, software and AI device submissions, change management, vigilance and PMS reporting, annual retention fees and renewal management.
  • Contact: hito.lin@grzan.cn; website www.grzan.cn.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail